256 related articles for article (PubMed ID: 11199321)
1. Predictors of erythropoietin responsiveness in chronic hemodialysis patients.
Tonelli M; Blake PG; Muirhead N
ASAIO J; 2001; 47(1):82-5. PubMed ID: 11199321
[TBL] [Abstract][Full Text] [Related]
2. Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response.
Gaweda AE; Goldsmith LJ; Brier ME; Aronoff GR
Clin J Am Soc Nephrol; 2010 Apr; 5(4):576-81. PubMed ID: 20110344
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human erythropoietin independence in chronic hemodialysis patients: clinical features, iron homeostasis and erythropoiesis.
Kuo CC; Lee CT; Chuang CH; Su Y; Chen JB
Clin Nephrol; 2005 Feb; 63(2):92-7. PubMed ID: 15730050
[TBL] [Abstract][Full Text] [Related]
5. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients.
Movilli E; Cancarini GC; Zani R; Camerini C; Sandrini M; Maiorca R
Nephrol Dial Transplant; 2001 Jan; 16(1):111-4. PubMed ID: 11209002
[TBL] [Abstract][Full Text] [Related]
6. Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload.
Lin CL; Hsu PY; Yang HY; Huang CC
Ren Fail; 2003 May; 25(3):445-53. PubMed ID: 12803508
[TBL] [Abstract][Full Text] [Related]
7. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
Ifudu O; Feldman J; Friedman EA
N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
[TBL] [Abstract][Full Text] [Related]
8. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients.
Gunnell J; Yeun JY; Depner TA; Kaysen GA
Am J Kidney Dis; 1999 Jan; 33(1):63-72. PubMed ID: 9915269
[TBL] [Abstract][Full Text] [Related]
9. Anemia in pediatric hemodialysis patients: results from the 2001 ESRD Clinical Performance Measures Project.
Frankenfield DL; Neu AM; Warady BA; Fivush BA; Johnson CA; Brem AS
Kidney Int; 2003 Sep; 64(3):1120-4. PubMed ID: 12911565
[TBL] [Abstract][Full Text] [Related]
10. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
[TBL] [Abstract][Full Text] [Related]
11. Anemia in hemodialysis patients: variables affecting this outcome predictor.
Madore F; Lowrie EG; Brugnara C; Lew NL; Lazarus JM; Bridges K; Owen WF
J Am Soc Nephrol; 1997 Dec; 8(12):1921-9. PubMed ID: 9402095
[TBL] [Abstract][Full Text] [Related]
12. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
13. Epoetin requirement does not depend on dialysis dose when Kt/N > 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores.
Movilli E; Cancarini GC; Vizzardi V; Camerini C; Brunori G; Cassamali S; Maiorca R
J Nephrol; 2003; 16(4):546-51. PubMed ID: 14696757
[TBL] [Abstract][Full Text] [Related]
14. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
Frankenfield DL; Johnson CA
Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
[TBL] [Abstract][Full Text] [Related]
15. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia.
Rao DS; Shih MS; Mohini R
N Engl J Med; 1993 Jan; 328(3):171-5. PubMed ID: 8417383
[TBL] [Abstract][Full Text] [Related]
16. Reduced requirement for erythropoietin with quotidian hemodialysis therapy.
Klarenbach S; Heidenheim AP; Leitch R; Lindsay RM;
ASAIO J; 2002; 48(1):57-61. PubMed ID: 11814098
[TBL] [Abstract][Full Text] [Related]
17. Trends in anemia management among US hemodialysis patients.
Coladonato JA; Frankenfield DL; Reddan DN; Klassen PS; Szczech LA; Johnson CA; Owen WF
J Am Soc Nephrol; 2002 May; 13(5):1288-95. PubMed ID: 11961017
[TBL] [Abstract][Full Text] [Related]
18. Intravenous calcitriol improves anaemia and reduces the need for erythropoietin in haemodialysis patients.
Goicoechea M; Vazquez MI; Ruiz MA; Gomez-Campdera F; Perez-García R; Valderrábano F
Nephron; 1998; 78(1):23-7. PubMed ID: 9453399
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience with darbepoietin alfa (NESP) in children undergoing hemodialysis.
De Palo T; Giordano M; Palumbo F; Bellantuono R; Messina G; Colella V; Caringella AD
Pediatr Nephrol; 2004 Mar; 19(3):337-40. PubMed ID: 14745634
[TBL] [Abstract][Full Text] [Related]
20. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
